secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2022-09-12T23:59:59+00:00
Accession:  0001628280-22-024744
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology plans randomized Phase 2 mCRC trial (ONSEMBLE) with topline data in 2H 2024; cash runway into 2025
--------------------------------------------------------------------------------

- Phase 1b/2 mCRC data show ORR 35%, mPFS 9.3 mo, median DoR 11.7 mo; historical controls ORR 5-13%, mPFS 4.5-5.7 mo.
- ONSEMBLE trial to enroll ~150 patients randomized 1:1:1 to SoC ± 20/30 mg onvansertib; primary endpoint ORR.
- Phase 2 PDAC trial: 1 PR, 3 SD in 5 evaluable patients; additional data expected Q2/Q3 2023.
- Company stops independent funding of prostate cancer program; will focus on mCRC and PDAC.
- Cash resources expected to fund operations into 2025; investigator-initiated trials in TNBC and SCLC ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022024744/0001628280-22-024744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022024744/crdf-20220910.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-024744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer